clevidipine has been researched along with arginine in 2 studies
| Studies (clevidipine) | Trials (clevidipine) | Recent Studies (post-2010) (clevidipine) | Studies (arginine) | Trials (arginine) | Recent Studies (post-2010) (arginine) |
|---|---|---|---|---|---|
| 127 | 19 | 62 | 46,388 | 1,688 | 11,176 |
| Protein | Taxonomy | clevidipine (IC50) | arginine (IC50) |
|---|---|---|---|
| Cationic amino acid transporter 3 | Homo sapiens (human) | 283 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gonon, A; Gourine, A; Pernow, J; Sjöquist, PO | 1 |
1 review(s) available for clevidipine and arginine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for clevidipine and arginine
| Article | Year |
|---|---|
Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxide-related mechanisms in the jeopardised myocardium.
Topics: Analysis of Variance; Animals; Arginine; Calcium Channel Blockers; Endothelium, Vascular; Enzyme Inhibitors; Female; Male; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Pyridines; Random Allocation; Substance P; Swine; Vascular Resistance | 2001 |